Letter
Medicine, General & Internal
Alexander M. Menzies, Ines Pires da Silva, Claudia Trojaniello
Summary: The study suggests that tumors that become resistant to PD-1 and LAG-3 therapy may also develop cross-resistance to ipilimumab.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Yao Xiao, Liang Mao, Qi-Chao Yang, Shuo Wang, Zhi-Zhong Wu, Shu-Cheng Wan, Meng-Jie Zhang, Zhi-Jun Sun
Summary: CD103+CD8+T cells are a subtype of T cells with excellent tumor killing ability and they respond to immune checkpoint blockade therapy in several types of cancer, but the phenotype, role and molecular mechanism of CD103+CD8+T cells in oral squamous cell carcinoma (OSCC) are still unclear.
Article
Immunology
Parviz Azimnasab-Sorkhabi, Maryam Soltani-Asl, Tulio Teruo Yoshinaga, Cristina de Oliveira Massoco, Jose Roberto Kfoury Junior
Summary: Cancer is classified into metabolic and/or genetic disorders, and the tryptophan catabolism pathway plays a vital role in different cancer types. This study focused on the interaction between the CTLA-4 receptor and IDO enzyme, and found that blocking IDO reduces the efficiency of anti-CTLA-4 antibody on cancer cell migration and clonogenic abilities. Further investigation into the molecular interaction between CTLA-4 and IDO could improve the efficacy of CTLA-4 immunotherapy.
IMMUNOLOGIC RESEARCH
(2023)
Article
Multidisciplinary Sciences
Roberta Zappasodi, Inna Serganova, Ivan J. Cohen, Masatomo Maeda, Masahiro Shindo, Yasin Senbabaoglu, McLane J. Watson, Avigdor Leftin, Rachana Maniyar, Svena Verma, Matthew Lubin, Myat Ko, Mayuresh M. Mane, Hong Zhong, Cailian Liu, Arnab Ghosh, Mohsen Abu-Akeel, Ellen Ackerstaff, Jason A. Koutcher, Ping-Chih Ho, Greg M. Delgoffe, Ronald Blasberg, Jedd D. Wolchok, Taha Merghoub
Summary: By blocking CTLA-4, metabolic fitness and immune cell infiltration in tumours, especially those with low glycolytic activity, can be enhanced. This improves therapeutic outcomes, particularly in tumours with defective glycolysis, by destabilizing T-reg cells and promoting the activity of tumour-specific CD8(+) T cells.
Review
Immunology
Carlo Genova, Chiara Dellepiane, Paolo Carrega, Sara Sommariva, Guido Ferlazzo, Paolo Pronzato, Rosaria Gangemi, Gilberto Filaci, Simona Coco, Michela Croce
Summary: The tumor microenvironment (TME) plays a crucial role in mediating the response to immunotherapy in non-small cell lung cancer (NSCLC). Modulating the TME towards an immunogenic state shows promise in enhancing the activity of immune checkpoint inhibitors (ICI). Clinical trials targeting TME components and investigating novel therapeutic targets are underway to improve the outcomes of cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Lujun Chen, Xiao Zheng, Hao Huang, Chen Feng, Shaoxian Wu, Rongzhang Chen, Hongwei Jiang, Maoling Yuan, Yuanyuan Fu, Hanjie Ying, Jun Zhou, Jingting Jiang
Summary: The strategy of combining immune checkpoint inhibitors (ICIs) with other therapies is important for enhancing cancer treatment. Cordycepin, an adenosine derivative, has shown promise in treating inflammation and cancer. Our research demonstrates that the combination of cordycepin and the anti-CD47 antibody effectively reduces tumor growth and extends the lifespan of tumor-bearing mice.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Oncology
Pushpamali De Silva, Marco Aiello, Chunyan Gu-Trantien, Edoardo Migliori, Karen Willard-Gallo, Cinzia Solinas
Summary: Immunotherapy approaches targeting immune checkpoint molecules like CTLA-4 have revolutionized treatment of solid tumors and hematological malignancies by enhancing antitumor immune responses. However, the use of anti-CTLA-4 Abs may lead to autoimmune-like adverse events, though this higher incidence is associated with improved clinical benefit.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Fangzhen Lin, Mengshang Xiong, Wei Hao, Yuewen Song, Ruoqi Liu, Yuanyuan Yang, Xiangfei Yuan, Dongmei Fan, Yizi Zhang, Mu Hao, Zhou Ye, Yang Lu, Yanjun Zhang, Jianxiang Wang, Dongsheng Xiong
Summary: A novel anti-CD47 blocking antibody named 2C8 has high affinity and tremendous anticancer effects, inducing macrophages to kill tumor cells in vitro and showing more effectiveness than the commercially available anti-CD47 mAb B6H12.2. In vivo, 2C8 controls tumor growth and extends survival of xenograft mice. Its antitumor ability may be applicable to various cancers.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, Mahdi Abdoli Shadbad, Farnaz Rasibonab, Hossein Safarpour, Vahid Jafarlou, Antonio Giovanni Solimando, Vito Racanelli, Pankaj Kumar Singh, Souzan Najafi, Darya Javadrashid, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran
Summary: The study revealed an increasing trend of CTLA-4 in colorectal cancer (CRC) and the inhibitory molecule can be suppressed by the chemotherapy drug capecitabine. Inhibiting CTLA-4 can reactivate immune cells against tumors, potentially enhancing treatment outcomes.
Article
Oncology
Mariam Oladejo, Wyatt Paulishak, Laurence Wood
Summary: Cancer vaccines and immune checkpoint inhibitors (ICIs) have different mechanisms of action in the cancer immune cycle. Cancer vaccines enhance immune cell activation and infiltration, while ICIs prevent dysfunction of immune cells. However, both therapies face challenges, such as attenuation of immune responses and adverse effects. Combining cancer vaccines with ICIs may provide a synergistic therapeutic platform. This review discusses the history, classifications, and mechanism of synergism between ICIs and cancer vaccines.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Oncology
Yang Wen, Fan Tang, Chongqi Tu, Francis Hornicek, Zhenfeng Duan, Li Min
Summary: This review discusses the use of immune checkpoint inhibitors (ICIs) in the treatment of osteosarcoma and their related mechanisms. Osteosarcoma treatment has had limited progress over the years, but the advent of ICIs provides a new therapeutic strategy. The current mechanisms of resistance to ICIs therapy in osteosarcoma are summarized, along with strategies to improve their efficacy and potential predictive biomarkers.
Article
Oncology
Julie Vackova, Ingrid Polakova, Shweta Dilip Johari, Michal Smahel
Summary: The study revealed the immunosuppressive role of CD80 in the tumor microenvironment and showed that deactivating CD80 in tumor cells increased sensitivity to CTLA-4 blockade. This suggests that CD80 may hold potential value in selecting cancer patients for immune checkpoint inhibitor therapy based on their sensitivity levels.
Article
Endocrinology & Metabolism
Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Keiko Wakahara, Kenji Yokota, Masashi Kato, Naoki Nishio, Chie Tanaka, Kazushi Miyata, Atsushi Ogura, Takanori Ito, Tsunaki Sawada, Tomoya Shimokata, Kaoru Niimi, Fumiharu Ohka, Masatoshi Ishigami, Momokazu Gotoh, Naozumi Hashimoto, Ryuta Saito, Hitoshi Kiyoi, Hiroaki Kajiyama, Yuichi Ando, Hideharu Hibi, Michihiko Sone, Masashi Akiyama, Yasuhiro Kodera, Hiroshi Arima
Summary: The study revealed that the incidence of thyroid immune-related adverse events was high after PD-1/CTLA-4-Abs treatment even in patients negative for ATAs at baseline.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Multidisciplinary Sciences
Anastasia Gangaev, Elisa A. Rozeman, Maartje W. Rohaan, Olga I. Isaeva, Daisy Philips, Sanne Patiwael, Joost H. van den Berg, Antoni Ribas, Dirk Schadendorf, Bastian Schilling, Ton N. Schumacher, Christian U. Blank, John B. A. G. Haanen, Pia Kvistborg
Summary: PD-1 blockade may primarily affect T cell composition in peripheral blood, while CTLA-4 blockade may result in the expansion of melanoma-reactive CD8 T cell response in peripheral blood.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Biochemistry & Molecular Biology
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.